Cancer research, Epithelial–mesenchymal transition, Cancer, Pathology and Mesenchymal stem cell are his primary areas of study. His Cancer research research includes themes of Cell culture, CD44, Cell growth, Immunology and Signal transduction. His Immunology research is multidisciplinary, relying on both Organ development, Gene targets, Disease and Neoplasm Invasiveness.
Epithelial–mesenchymal transition is a primary field of his research addressed under Metastasis. His Cancer study combines topics in areas such as Phenotype, Cell and Epidermal growth factor. His research integrates issues of Muscle hypertrophy, Tibia, Matrix metalloproteinase and In vivo in his study of Pathology.
His primary scientific interests are in Cancer research, Pathology, Epithelial–mesenchymal transition, Metastasis and Cancer. His Cancer research study combines topics from a wide range of disciplines, such as Cell culture, Cell, Cancer cell, Immunology and Breast cancer. His Pathology study integrates concerns from other disciplines, such as Downregulation and upregulation and In vivo.
His study in Epithelial–mesenchymal transition is interdisciplinary in nature, drawing from both Epidermal growth factor, Mesenchymal stem cell, Cell biology, Vimentin and Tumor progression. The Metastasis study combines topics in areas such as Cancer stem cell, Carcinoma and Angiogenesis. Erik W. Thompson interconnects Phenotype and Endocrinology in the investigation of issues within Cancer.
His primary scientific interests are in Cancer research, Epithelial–mesenchymal transition, Breast cancer, Metastasis and Internal medicine. The various areas that he examines in his Cancer research study include Cancer, Tumor progression, Cell, Regulator and Mesenchymal stem cell. His Epithelial–mesenchymal transition research is multidisciplinary, incorporating elements of Epidermal growth factor, Gene expression profiling, Cell biology, Vimentin and MDA-MB-468.
His Breast cancer research incorporates themes from Carcinoma in situ, Signal transduction and Pathology. His study looks at the relationship between Metastasis and topics such as Cancer cell, which overlap with Cell adhesion and Reactive oxygen species. His work deals with themes such as Endocrinology and Oncology, which intersect with Internal medicine.
Erik W. Thompson spends much of his time researching Cancer research, Epithelial–mesenchymal transition, Metastasis, Breast cancer and Internal medicine. His biological study spans a wide range of topics, including Cancer, Tumor progression, Epidermal growth factor, Cell and Immunology. His Epithelial–mesenchymal transition research includes elements of Cadherin, Gene expression profiling, Cell biology, Regulator and Transforming growth factor beta.
His work carried out in the field of Metastasis brings together such families of science as Cancer cell, Phenotype, Mesenchymal stem cell and Stem cell. The concepts of his Breast cancer study are interwoven with issues in Clinical trial, Pathology, Intermittent hypoxia, Downregulation and upregulation and Signal transduction. His Internal medicine study incorporates themes from Endocrinology and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The epithelial–mesenchymal transition: new insights in signaling, development, and disease
Jonathan M. Lee;Shoukat Dedhar;Raghu Kalluri;Raghu Kalluri;Raghu Kalluri;Erik W. Thompson;Erik W. Thompson.
Journal of Cell Biology (2006)
Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.
Honor Hugo;M. Leigh Ackland;Tony Blick;Mitchell G. Lawrence.
Journal of Cellular Physiology (2007)
Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?
Erik W. Thompson;Donald F. Newgreen.
Cancer Research (2005)
The fallacy of epithelial mesenchymal transition in neoplasia.
David Tarin;Erik W Thompson;Donald F Newgreen.
Cancer Research (2005)
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.
Erik W. Thompson;Soonmyoung Paik;Nils Brünner;Connie L. Sommers.
Journal of Cellular Physiology (1992)
MATRIX METALLOPROTEINASE-13 DEFICIENT MICE ARE RESISTANT TO OSTEOARTHRITIC CARTILAGE EROSION BUT NOT CHONDROCYTE HYPERTROPHY OR OSTEOPHYTE DEVELOPMENT
C. B. Little;A. Barai;D. Burkhardt;S. M. Smith.
Arthritis & Rheumatism (2009)
Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.
Reuven Reich;Erik W. Thompson;Yukihide Iwamoto;George R. Martin.
Cancer Research (1988)
Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
Hirokazu Nakahara;Linda Howard;Erik W. Thompson;Hiroshi Sato.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Mesenchymal-to-Epithelial Transition Facilitates Bladder Cancer Metastasis: Role of Fibroblast Growth Factor Receptor-2
Christine L. Chaffer;Janelle P. Brennan;Janelle P. Brennan;John L. Slavin;Tony Blick.
Cancer Research (2006)
Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo
Maria I. Kokkinos;Razan Wafai;Meng Kang Wong;Donald F. Newgreen.
Cells Tissues Organs (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: